Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDOZPU)

Drug Name

PK 11195 Drug Info

Synonyms

1-(2-Chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; 85532-75-8; PK-11195; PK11195; RP 52028; BRN 4264456; CHEBI:73290; N-sec-butyl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; N-(butan-2-yl)-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide; 3-Isoquinolinecarboxamide, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-; SMR000058427; SR-01000076240; Biomol-NT_000287; AC1L1B9T; DSSTox_RID_79625; Interferon alfa (IFN-alpha)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 1345
ChEBI ID: CHEMBL481537
CAS Number: CAS 85532-75-8
TTD Drug ID: DMDOZPU

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Fibroblast growth factor receptor 2 (FGFR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pemigatinib	DM819JF	Cholangiocarcinoma	2C12.10	Approved	[6]
Interferon Alfa-2a, Recombinant	DMUTZ8S	Chronic HCV-1 infection	1E51.1	Approved	[1]
Palifermin	DM9JOYP	Oral mucositis	DA01.11	Approved	[7]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Trafermin	DMLKI2B	Periodontitis	DA0C	Phase 3	[9]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
LY2874455	DMZ0DMY	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[12]
AEE-788	DMEOS5K	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]
BAY1179470	DM7L91K	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Translocator protein (TSPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[15]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[16]
Oxazepam	DMXNZM4	Alcohol withdrawal delirium		Approved	[17]
Midazolam	DMXOELT	Agitation	6A70.3	Approved	[18]
Temazepam	DM02A65	Insomnia	7A00-7A0Z	Approved	[18]
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[19]
Alprazolam	DMC7XDN	Anxiety		Approved	[16]
Clotiazepam	DM59AZT	Anxiety disorder	6B00-6B0Z	Approved	[20]
Quazepam	DMY4D87	Insomnia	7A00-7A0Z	Approved	[18]
Eszopiclone	DM8RZ9H	Insomnia	7A00-7A0Z	Approved	[21]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[22]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[23]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[24]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[27]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[28]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[29]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[30]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[32]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[32]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[33]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[34]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[35]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[32]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[32]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[32]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[22]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[36]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[37]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[38]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[39]
Selenium	DM25CGV	N. A.	N. A.	Approved	[40]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[41]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[42]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[43]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[44]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[45]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[46]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor 2 (FGFR2)	TTGJVQM	FGFR2_HUMAN	Binder	[1]
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Binder	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[3]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[4]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

References

1	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
2	Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001 Nov 30;85(11):1771-80.
3	Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol. 2004 Nov;41(5):799-807. doi: 10.1016/j.jhep.2004.07.015.
4	Improved assays for xenosensor activation based on reverse transfection. Toxicol In Vitro. 2015 Oct;29(7):1759-65. doi: 10.1016/j.tiv.2015.07.011. Epub 2015 Jul 14.
5	Modulation of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) by 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives, ligands of peripheral benzodiazepine receptor (PBR). Toxicol Lett. 2011 Apr 25;202(2):148-54.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7	Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87.
8	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
9	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	Company report (Eli Lilly) (drug: LY2874455)
12	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
13	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
14	National Cancer Institute Drug Dictionary (drug id 751593).
15	Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
16	Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
17	Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
18	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
19	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
20	Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
21	New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
22	Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
23	Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
24	Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
25	Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
26	Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
27	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
28	Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
29	Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
30	Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
31	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
32	Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
33	Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
34	Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
35	Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
36	Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
37	Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
38	Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
39	Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
40	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
41	Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
42	Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
43	Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
44	Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
45	Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
46	Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.